F2-isoprostanes: Sensitive and specific non-invasive indices of lipid peroxidation in vivo

Atherosclerosis

Volumn 147, Issue 1, 1999, Pages 1-10

  Praticò, Domenico ^a  

^a Center for Experimental Therapeutics   (United States)

Author keywords

F2 isoprostanes; Lipid peroxidation; Oxidant stress

Indexed keywords

7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; INDOMETACIN; ISOPROSTANE; LIPID; LOW DENSITY LIPOPROTEIN; POLYUNSATURATED FATTY ACID; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ALZHEIMER DISEASE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; GAS CHROMATOGRAPHY; HEART MUSCLE ISCHEMIA; HUMAN; LIPID PEROXIDATION; LIVER INJURY; MASS SPECTROMETRY; METABOLISM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REPERFUSION INJURY; THROMBOCYTE ACTIVATION;

EID: 0032828451     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00257-9     Document Type: Review

References (92)

1. Pryor W.A., Stanley J.P., Blair E. Auto-oxidation of polyunsaturated fatty acid: II. A suggested mechanism for the formation of TBA-reactive materials from prostaglandin-like endoperoxides. Lipids. 11:1976;370-379.
2. Porter N.A., Funk M.O. Peroxyl radical cyclization as a model for prostaglandin biosynthesis. J. Org. Chem. 40:1975;3614-3615.
3. Mihelich E.D. Structurae and stereochemistry of novel endoperoxides isolated from the sensitized photo-oxidation of methyl linoleate. Implication for prostaglandin biosynthesis. J. Am. Chem. Soc. 102:1980;7141-7143.
4. O'Connor D.E., Mihelich E.D., Coleman M.C. Stereochemical course of the autoxidative cyclization of lipid hydroperoxydes to prostaglandin-like bicyclo endoperoxides. J. Am. Chem. Soc. 106:1984;3577-3584.
5. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. USA. 87:1990;9383-9387.
6. 3-isoprostanes during peroxidation of eicosapentaenoic acid. Biochem. Biophys. Res. Comm. 236:1997;467-472.
7. Roberts L.J., Montine T.J., Markesberry W.R., Tapper A.R., Hardy P., Chemtob S., Dettbarn W.D., Morrow J.D. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J. Biol. Chem. 273:1998;13605-13612.
8. Morrow J.D., Minton T.A., Mukundan C.R., Campbell M.D., Zackert W.E., Daniel V.C., Badr K.F., Blair I.A., Roberts L.J. Free radical-induced generation of isoprostanes in vivo. Evidence for the formation of D-ring and E-ring isoprostanes. J. Biol. Chem. 269:1994;4317-4326.
9. Morrow J.D., Awad J.A., Wu A., Zackert A., Daniel V.C., Roberts L.J. Nonenzymatic free radical-catalyzed generation of thromboxane-like compounds (Isothromboxanes) in vivo. J. Biol. Chem. 271:1996;23185-23190.
10. Harrison K.A., Murphy R.C. Isoleukotrienes are biologically active free radical products of lipid peroxidation. J. Biol. Chem. 270:1995;17273-17278.
11. 2-isoprostanes to plaque instability in human carotid atherosclerosis. J. Clin. Invest. 103:1999;421-427.
12. 2-isoprostanes formed by free radical oxidation of arachidonic acid. J. Am. Soc. Mass. Spectrom. 7:1996;490-499.
13. 2-isoprostanes) are formed in situ in phospholipids. Proc. Natl. Acad. Sci. USA. 89:1992;10721-10725.
14. 2α. J. Biol. Chem. 270:1995;9800-9808.
15. 2α by human monocytes. Discriminate production by reactive oxygen species and PG G/H S-2. J Biol Chem 1996;271:8919-8924.
16. 2-isoprostane formation. Br. J. Pharmacol. 118:1996;1285-1293.
17. Reilly M., Delanty N., Lawson J.A., FitzGerald G.A. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation. 94:1996;19-25.
18. 2α-III, an index of oxidant stress. Am. J. Resp. Crit. Care. Med. 158:1998;1709-1714.
19. 2: an index of thromboxane formation in the human circulation. Proc. Natl. Acad. Sci. USA. 83:1986;5861-5865.
20. 2α. A novel strategy for the synthesis of isoprostanes. J. Am. Chem. Soc. 116:1994;10829-10830.
21. 2α-I and its identification in biological fluids. Tetrahedron Lett. 37:1996;4849-4852.
22. Rokach J., Khanapure S.P., Hwang S.W., Adiyaman M., Lawson J.A., FitzGerald G.A. The isoprostanes: a perspective. Prostaglandins. 54:1997;823-851.
23. Taber D.F., Morrow J.D., Roberts L.J. A nomenclature system for the isoprostanes. Prostaglandins. 53:1997;63-67.
24. Rokach J., Khanapure S.P., Hwang S.W., Adiyaman M., Lawson J.A., FitzGerald G.A. Nomenclature of Isoprostanes: a proposal. Prostaglandins. 54:1997;853-873.
25. 2α-I: A novel index of lipid peroxidation in humans. Proc. Natl. Acad. Sci. USA. 95:1998;3449-3454.
26. Halliwell B., Chirico S. Lipid peroxidation: its mechanism, measurement and significance. Am. J. Clin. Nutr. 57:1993;715S-725.
27. Gutteridge J.M.C., Halliwell B. The measurement and mechanism of lipid peroxidation in biological systems. Trends Biochem. Sci. 15:1990;129-1365.
28. Fruebis J., Bird D.A., Pattison J., Palinski W. Extent of antioxidant protection of plasma LDL is not a predictor of the antiatherogenic effect of antioxidants. J. Lipid Res. 38:1997;2455-2464.
29. 2α: specific analysis of an isoeicosanoid as an index of oxidant stress in vivo. Br. J. Clin. Pharmacol. 42:1996;15-19.
30. Patrono C., FitzGerald G.A. Isoprostanes: Potential markers of oxidant stress in atherothrombotic disease. Arterioscler. Thromb. Vasc. Biol. 17:1997;2309-2315.
31. Roberts L.J., Morrow J.D. The generation and actions of isoprostanes. Biochim. Biophys. Acta. 1345:1997;121-135.
32. 2-isoprostanes. Agents Action. 48(S):1997;25-41.
33. 2-isoprostanes) in carbon tetrachloride hepatotoxicity. J. Clin. Invest. 90:1992;2502-2507.
34. 2α in humans. J. Biol. Chem. 271:1996;20617-20620.
35. 2α. J. Biol. Chem. 274:1999;1313-1319.
36. Frolich J.C., Wilson T.W., Sweetman B.J., Smigel M., Nies A.S., Carr K., Watson J.T., Oates J.A. Urinary prostaglandins. Identification and origin. J. Clin. Invest. 55:1975;763-770.
37. Catella F., Nowack J., FitzGerald G.A. Measurement of renal and non-renal eicosanoid synthesis. Am. J. Med. 81(2B):1986;23-29.
38. 2 formation in the human circulation. Proc. Natl. Acad. Sci. USA. 83:1986;5861-5865.
39. 2-isoprostanes produced by non-cylcooxygenase free radical-catalyzed mechanism. Meth. Enzymol. 233:1994;163-174.
40. 2α-VI, in human urine. J. Biol. Chem. 273:1998;29295-29301.
41. 2α, a novel index of lipid peroxidation in vivo, by immunoaffinity extraction/gas chromatography-mass spectrometry. Basal levels in smokers and nonsmokers. Free Rad. Biol. Med. 20:1996;619-624.
42. 2 antibodies. Biochem. Biophys. Res. Comm. 206:1995;455-461.
43. 2α excretion in man. J. Pharmacol. Exp. Ther. 275:1995;94-100.
44. 2α, in the rat. J. Clin. Invest. 90:1992;136-141.
45. 2α in isolated perfused rat lung. J. Appl. Physiol. 74:1993;460-465.
46. 2α, in rabbit lung in situ. Am. J. Physiol. 263:1992;H660-H663.
47. 2α. Br. J. Pharmacol. 119:1996;1276-1280.
48. 2α induces airflow obstruction and airway plasma exudation in vivo. Am. J. Resp. Cr. Care. Med. 155:1997;436-441.
49. Hoffman S.W., Moore S., Ellis E.F. Isoprostanes: free radical-generated prostaglandins with constrictor effects on cerebral arterioles. Stroke. 28:1997;844-849.
50. 2α on retinal vessels. Am. J. Physiol. 43:1998;R1406-1416.
51. 2-isoprostane receptors on rat vascular smooth muscle cells. Am. J. Physiol. 264:1993;C1619-C1624.
52. 2α is not mediated by thromboxane receptor isoforms. J. Biol. Chem. 271:1996;14916-14924.
53. 2α, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. Prostaglandins. 44:1992;155-163.
54. 2α increases platelet adhesion and reduces the antiadhesive and antiaggregatory effects of NO. Arterioscler. Thromb. Vasc. Biol. 8:1998;1248-1256.
55. 2α. J. Biol. Chem. 272:1997;27147-27154.
56. 2α-III, induce cardiomyocytes hypertrophy. J. Biol. Chem. 273:1998;22442-22452.
57. Steinberg D. Oxidative modification of LDL and atherogenesis. Circulation. 95:1997;1062-1071.
58. Heinecke J.W. Oxidants and antioxidants in the pathogenesis of atherosclerosis: implication for the oxidized low density lipoprotein hypothesis. Atherosclerosis. 141:1988;1-15.
59. Witztum J.I., Berliner J.A. Oxidized phospholipids and isoprostanes in atherosclerosis. Curr. Op. Lipid. 9:1998;441-448.
60. 2-isoprostanes and malondialdehyde in peroxidizing rat liver microsomes. Biochem. Pharmacol. 47:1994;1173-1177.
61. 2-isoprostanes) in plasma and low-density lipoprotein exposed to oxidative stress in vitro. J. Clin. Invest. 93:1994;998-1004.
62. 2-isoprostanes during oxidation of low-density lipoprotein and plasma by peroxynitrite. Circ. Res. 77:1995;335-341.
63. 2-isoprostanes during aortic endothelial cell-mediated oxidation of low-density lipoprotein. FEBS Lett. 348:1994;297-300.
64. 2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N. Engl. J. Med. 332:1995;1198-1203.
65. 2α levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett. 368:1995;225-229.
66. Catella-Lawson F., Kapoor S., Praticò D., Braunstein S.N., Caraballo V., FitzGerald G.A. Oxidative stress and diabetes mellitus. J. Invest. Med. 44:1996;223A.
67. 2α and platelet activation in diabetes mellitus. Effects of improved metabolic control and vitamin E supplementation. Circulation. 99:1999;224-229.
68. 2α is increased in hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 17:1997;3230-3235.
69. 2-isoprostanes in hypercholesterolemia. Circulation. 98:1998;2822-2828.
70. Vaarala O., Manttari M., Manninen V., Tenkanen L., Puurunen M., Aho K., Palosuo T. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation. 91:1995;23-27.
71. Iuliano L., Praticò D., Ferro D., Pittone V., Valesini G., Lawson J., FitzGerald G.A., Violi F. Enchanced lipid peroxidation in patients positive for antiphospholipid antibodies. Blood. 90:1997;3931-3935.
72. Praticò D., Ferro D., Iuliano L., Rokach J., Conti F., Valesini G., FitzGerald G.A., Violi F. Systemic clotting activation in patients with antiphospholipid antibodies: a role for lipid peroxidation. Blood. 93:1999;3401-3407.
73. Davies S.W., Ranjadayalan K., Wickens D.G., Dormandy T.L., Timmis A.D. Lipid peroxidation associated with successful thrombolysis. Lancet. 335:1990;741-743.
74. Kloner R.A., Pryklenk K., Whittaker P. deleterious effects of oxygen radicals in ischemia/reperfusion: unresolved issues. Circulation. 80:1989;1115-1127.
75. 2α generation during coronary reperfusion: a potential quantitative marker of oxidant stress in vivo. Circulation. 95:1997;2492-2499.
76. 2α in acute coronary angioplasty: evidence for oxidant stress during coronary reperfusion in humans. Circulation. 96:1997;3314-3320.
77. 2-isoprostanes in human atherosclerotic lesions. J. Clin. Invest. 100:1997;2028-2034.
78. 2-isoprostanes, are present in increased amounts in human atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 17:1997;3236-3241.
79. 2-isoprostanes to plaque instability in human carotid atherosclerosis. J. Clin. Invest. 103:1999;421-427.
80. Repine J.E., Bast A., Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Am. J. Resp. Crit. Care. Med. 156:1997;341-357.
81. Montuschi P., Ciabattoni P., Paredi P., Pantelidis P., du Bois R.M., Kharitonov S.A. et al. 8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. Am. J. Resp. Crit. Care. Med. 158:1998;1524-1527.
82. Reilly M, Praticò D, Lanken P, Delanty N, Rokach J, Lawson JA, FitzGerald. Isoprostanes in the assessment of oxidant stress in vivo. In: Serhan CN, Ward PA, editors. Molecular and Cellular basis of Inflammation. Humana Press, 1998, pp. 127-139.
83. 2-isoprostanes) in the hepatorenal syndrome. J. Lipid Med. 6:1993;417-420.
84. Praticò D., Iuliano L., Basili S., Ferro D., Camastra C., Cordova C., Riggio O., FitzGerald G.A., Violi F. Enhanced lipid peroxidation in hepatic cirrhosis. J. Invest. Med. 46:1998;51-57.
85. Aleynik S.I., Leo A.M., Aleynik M.K., Lieber C.S. Increased circulating products of lipid peroxidation in patients with alcoholic liver disease. Alcohol Clin. Exp. Res. 22:1998;192-196.
86. 2-isoprostane and 4-hydroxynonenal excretion in human bile of patients with biliary tract and pancreatic disorders. Am. J. Gastroenterol. 92:1997;2069-2072.
87. 2α, a product of lipid peroxidation, increases portal pressure in normal and cirrhotic rats. Gastroenterology. 112:1997;208-213.
88. 2α-III, a marker of lipid peroxidation, do not correlate with increased portal pressure in cirrhotic patients. J. Invest. Med. 46:1998;430-434.
89. Beal M.F. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38:1995;357-366.
90. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Rad. Biol. Med. 23:1997;134-147.
91. 2-isoprostanes in Alzheimer's disease: evidence of enhanced lipid peroxidation in vivo. FASEB J. 12:1998;1777-1783.
92. 2-isoprostanes concentration in probable AD. Neurology. 52:1999;562-565.